VNRX News and Press, VolitionRX Limited From 06/01/23

VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock PR Newswire HENDERSON, Nev. , June 1, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics comp...

2023-06-01 08:32:17 ET VolitionRx ( NYSE: VNRX ) prices an underwritten public offering of shares, whereby underwriters will be granted a 30-day option to purchase up to an additional 15% shares. The final terms and size of the offering will depend on market and othe...

2023-06-01 08:30:01 ET Okta OKTA -19% after Q1earning release . Lexicon Pharmaceuticals ( LXRX ) -18% announces pricing of $125 Million public offering and concurrent private placement. C3.ai AI -17% after Q4 earning release . Victoria's Secret &...

2023-05-11 13:29:05 ET VolitionRx Limited (VNRX) Q1 2023 Earnings Call May 11, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations. Cameron Reynolds - President and Group Chief Executive Officer Tom Butera - Chief Ex...

Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring PR Newswire HENDERSON, Nev. , May 11, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces n...

VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update PR Newswire Conference call to discuss financial and operational results scheduled for Thursday, May 11 , at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , May 10...

2023-05-10 14:31:08 ET VolitionRX ( NYSE: VNRX ) is scheduled to announce Q1 earnings results on Thursday, May 11th, before market open. The consensus EPS Estimate is -$0.14 and the consensus Revenue Estimate is $0.42M. Over the last 3 months, EPS estimates have seen 1...

VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11. PR Newswire HENDERSON, Nev. , April 26, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company is hosting a Capital Marke...

2023-03-29 11:45:03 ET The following slide deck was published by VolitionRx Limited in conjunction with this event. For further details see: VolitionRX (VNRX) Investor presentation - Slideshow

2023-03-16 13:34:02 ET VolitionRx Limited (VNRX) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Scott Powell – Executive Vice President-Investor Relations Cameron Reynolds – President and Group Chief Executive Officer ...